Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totaling 129,033 shares, a decline of 32.8% from the June 30th total of 191,938 shares. Based on an average daily volume of 32 shares, the short-interest ratio is presently 4,032.3 days. Approximately 0.1% of the shares of the company are sold short.
Recordati Industria Chimica E Farmaceutica Price Performance
Recordati Industria Chimica E Farmaceutica stock opened at $58.00 on Friday. The company has a market capitalization of $11.97 billion, a P/E ratio of 20.69 and a beta of 0.25. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.86 and a current ratio of 1.26. Recordati Industria Chimica E Farmaceutica has a fifty-two week low of $55.88 and a fifty-two week high of $60.00. The stock has a 50-day simple moving average of $58.71 and a 200-day simple moving average of $59.35.
Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.91 earnings per share for the quarter. The company had revenue of $810.70 million during the quarter. Recordati Industria Chimica E Farmaceutica had a return on equity of 34.46% and a net margin of 18.38%.
Recordati Industria Chimica E Farmaceutica Company Profile
Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.
The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.
Featured Stories
- Five stocks we like better than Recordati Industria Chimica E Farmaceutica
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
Receive News & Ratings for Recordati Industria Chimica E Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica E Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
